Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
This study was terminated on 19 Apr 2010 due to unfavorable risk benefit ratio which did not support continuation in part 2 of the study. Even if the safety profile of the combination of Bosutinib and Exemestane was acceptable 25% of subjects had treatment related liver events including 14% of severe liver events.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Woman aged 18 years or older.
Confirmed pathologic diagnosis of breast cancer.
Locally advanced, metastatic, or locoregional recurrent breast cancer not amenable to curative treatment with surgery or radiotherapy.
Surgically sterile or postmenopausal woman.
Documented ER+ and/or PgR+ and erbB2- tumor.
Progression of locally advanced or metastatic disease during treatment with a nonsteroidal AI or tamoxifen, or progression during treatment with (or within 6 months of discontinuation of) an adjuvant nonsteroidal AI.
You may not be if
Prior exemestane, prior bosutinib, or any other prior anti-Src therapy.
More than 1 prior endocrine treatment for locally advanced or MBC.
More than 1 prior cytotoxic chemotherapy regimen in metastatic setting.
